The Future of Medicine:
Human Tissue Therapeutics
A tissue therapeutics company – built on DeepTech innovation – offering a scalable solution to restore lost tissue and organ function for millions of patients.
The Problem
Tissue Dysfunction
Every 30 seconds, a patient dies from a disease caused by tissue dysfunction. After decades of research, we still lack reliable solutions to restore lost cell and organ function. Injectable cell therapies underdeliver due to limited cell retention and organ transplantation is highly limited.
The Solution
Tissue Therapeutics
The Tech Stack (Part 1)
Light-based Biofabrication
The Tech Stack (Part 2)
AI-driven Tissue Engineering
Our AI-driven tissue engineering software generates precise building plans of tissue therapeutics incorporating the final bioarchitecture and actively supports the biofabrication process to ensure error-free tissue production using deep learning–based process control and AI-guided fluid dynamics.
The Problem
Tissue Dysfunction
Every 30 seconds, a patient dies from a disease caused by tissue dysfunction. After decades of research, we still lack reliable solutions to restore lost cell and organ function. Injectable cell therapies underdeliver due to limited cell retention and organ transplantation is highly limited.
The Solution
Tissue Therapeutics
We develop advanced, cell-based human tissue therapeutics to treat conditions with no solutions. Our biofabricated tissues are validated in vivo and functional, scalable, and immune-compatible – engineered to integrate seamlessly with the body and restore soft tissue defects and organ function.
The Tech Stack (Part 1)
Light-based Biofabrication
Our proprietary light-based biofabrication system integrates deeptech, AI-driven tissue engineering, and biomedicine to produce human tissue therapeutics at scale. It combines human cells with custom biomaterials in a highly scalable and versatile manufacturing process.
The Tech Stack (Part 2)
AI-driven Tissue Engineering
Our AI-driven tissue engineering software generates precise building plans of tissue therapeutics incorporating the final bioarchitecture and actively supports the biofabrication process to ensure error-free tissue production using deep learning–based process control and AI-guided fluid dynamics.
Selected Partners and Supporters
Alongside backing from our institutional investors, Cellbricks and its technology have received invaluable support from leading organizations and strategic collaborators.
Selected News and Media Features
Trusted media sources are sharing our journey. Find the latest company press releases and features below.
PitchBook Lists Cellbricks Among the Most Promising Biofabrication Companies Worldwide
- Feature | PitchBook |
Startup of the Week: Cellbricks – 3D Bioprinting Human Tissue | (Gründer*in der Woche: Cellbricks – menschliches Gewebe per 3D-Druck)
- Feature | StartingUp |
Germany’s Economic Crisis: How Future Business Models Could Look Like | (Wirtschaft in der Krise: Braucht Deutschland ein neues Geschäftsmodell?)
- Feature | ZDF |
Former BioNTech CFO Michael Kring Joins Cellbricks as Chief Financial Officer
- Press release |
Former J&J and Novartis Executive, Dr. Kathy Kordy, M.D. Joins Cellbricks as Chief Medical Officer
- Press release |
